Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection.

Five patients with chronic hepatitis B were treated with 8-day courses of leukocyte (alpha) interferon (5 X 10(6) U/day) and with 8-day courses of recombinant fibroblast (betaser) interferon at dosages of 5 X 10(6), 35 X 10(6), and 105 X 10(6) U/day. Inhibition of hepatitis B virus replication as ev...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Yayımlandı:	Antimicrob Agents Chemother
Asıl Yazarlar:	Eisenberg, M, Rosno, S, Garcia, G, Konrad, M W, Gregory, P B, Robinson, W S, Merigan, T C
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	American Society for Microbiology (ASM) 1986
Konular:	Research Article
Online Erişim:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC180376/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3524420/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.29.1.122
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection.

Benzer Materyaller